Burcu Acar ÇİNLETİ, Nilgül YARDIMCI, Zübeyde AYTÜRK, Atilla İLHAN, Gülhan KAYA, Muradiye ACAR, Emine Rabia KOÇ, Esra GÜNDÜZ, Mehmet GÜNDÜZ

The effects and interactions of APOE and APH-1A polymorphisms in Alzheimer disease

Background/aim: Alzheimer disease (AD) is characterized by the accumulation of senile plaques composed of amyloid β-peptide, which is derived from β-amyloid precursor protein through degradation by β-secretase and γ-secretase complexes. One of the major components of γ-secretase complex, anterior pharynx-defective-1 (APH-1), is responsible for the activity of the γ-secretase complex. In this study, we searched for not only the most known common genetic risk factor, APOE, but also the APH-1a gene polymorphism in AD patients in a Turkish population. Materials and methods: In this study, 49 AD patients and 45 healthy controls were included. The genetic polymorphisms and allele frequencies of APOE and APH-1a were investigated. Patients were evaluated for behavioral, cognitive, and functional domains by detailed neurocognitive tests, and comparison between the above-mentioned polymorphisms and disease severity was made. Results: Although there was an increased tendency of the APO ?4 allele in the AD group, no statistically significant difference was detected either in APOE or APH-1a polymorphisms, not suggesting a strong susceptibility to the development of AD. Conclusion: While searching for the pathogenesis of AD in order to develop novel diagnostic as well as therapeutic approaches, analysis of other genes with a possible role in AD is warranted.

Anahtar Kelimeler:

Alzheimer disease, APOE, APH-1A, polymorphism, biomarker

The effects and interactions of APOE and APH-1A polymorphisms in Alzheimer disease

Keywords:

Alzheimer disease, APOE, APH-1A, polymorphism, biomarker,

PDF

___

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s Disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939–944. 2. Dewan MJ, Gupta S. Toward a definite diagnosis of Alzheimer’s disease. Compr Psychiatry 1992; 33: 282–290.
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging- Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 263–269.
Chouliaras L, Sierksma AS, Kenis G, Prickaerts J, Lemmens MA, Brasnjevic I, van Donkelaar EL, Martinez-Martinez P, Losen M, De Baets MH et al. Gene-environment interaction research and transgenic mouse models of Alzheimer’s disease. Int J Alzheimers Dis 2010; 2010: 1–27.
Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 2014; 88: 640–651. 6. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. P Natl Acad Sci USA 1995; 92: 4725–4727. 7. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000; 1: 507–537.
Boschert U, Merlo-Pich E, Higgins G, Roses AD, Catsicas S. Apolipoprotein E expression by neurons surviving excitotoxic stress. Neurobiol Dis 1999; 6: 508–514. 9. Brecht WJ, Harris FM, Chang S, Tesseur I, Yu GQ, Xu Q, Dee Fish J, Wyss-Coray T, Buttini M, Mucke L et al. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci 2004; 24: 2527–2534.
Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 2004; 10: 1055–1063.
Consensus report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Neurobiol Aging 1998; 19: 109–116.
Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD, Rogers J, Siemers E, Trojanowski JQ; National Institute on Aging Biological Markers Working Group. Biological markers for therapeutic trials in Alzheimer’s disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer’s disease. Neurobiol Aging 2003; 24: 521–536.
Braak H, Braak E. Neuropathological stageing of Alzheimer- related changes. Acta Neuropathol 1991; 82: 239–259.
Butterfield DA, Pocernich CB, Wilcock GK. The glutamatergic system and Alzheimer’s disease. CNS Drugs 2003; 17: 641–652.
De Strooper B. Aph-1, Pen-2, and Nicastrin with presenilin generate an active gamma-secretase complex. Neuron 2003; 38: 9–12.
Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R et al. Beta- secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286: 735–741.
Hansson CA, Frykman S, Farmery MR, Tjernberg LO, Nilsberth C, Pursglove SE, Ito A, Winblad B, Cowburn RF, Thyberg J et al. Nicastrin, presenilin, APH-1, and PEN-2 form active gamma-secretase complexes in mitochondria. J Biol Chem 2004; 279: 51654–51660.
Baulac S, LaVoie MJ, Kimberly WT, Strahle J, Wolfe MS, Selkoe DJ, Xia W. Functional gamma-secretase complex assembly in Golgi/trans-Golgi network: interactions among presenilin, nicastrin, Aph1, Pen-2, and gamma-secretase substrates. Neurobiol Dis 2003; 14: 194–204.
Lv H, Jia L, Jia J. Promoter polymorphisms which modulate APP expression may increase susceptibility to Alzheimer’s disease. Neurobiol Aging 2008; 29: 194–202.
Arawaka S, Hasegawa H, Tandon A, Janus C, Chen F, Yu G, Kikuchi K, Koyama S, Kato T, Fraser PE et al. The levels of mature glycosylated nicastrin are regulated and correlate with gamma-secretase processing of amyloid beta-precursor protein. J Neurochem 2002; 83: 1065–1071.
Qin W, Jia L, Zhou A, Zuo X, Cheng Z, Wang F, Shi F, Jia J. The -980C/G polymorphism in APH-1A promoter confers risk of Alzheimer’s disease. Aging Cell 2011; 10: 711–719.
Wang Y, Jia J. Association between promoter polymorphisms in anterior pharynx-defective-1a and sporadic Alzheimer’s disease in the North Chinese Han population. Neurosci Lett 2009; 455: 101–104.
Poli M, Gatta LB, Archetti S, Padovani A, Albertini A, Finazzi D. Association analysis between anterior-pharynx defective-1 genes polymorphisms and Alzheimer’s disease. Neurosci Lett 2003 ; 350: 77–80.
Rassas AA, Mrabet KH, Hadj FS, Sahnoun S, Batti H, Oudiaa ZN, Cherif A, Anane N, Ben AN, Messaoud T et al. High APOE epsilon 4 allele frequencies associated with Alzheimer disease in a Tunisian population. Neurol Sci 2012; 33: 33–37.
Boustani M, Peterson B, Hanson L, Harris R, Lohr KN; U.S. Preventive Services Task Force. Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2003; 138: 927–937.
Blacker D, Haines JL, Rodes L, Terwedow H, Go RC, Harrell LE, Perry RT, Bassett SS, Chase G, Meyers D et al. ApoE-4 and age at onset of Alzheimer’s disease: the NIMH genetics initiative. Neurology 1997; 48: 139–147.
Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis JC, Smith AV, Carassquillo MM, Lambert JC et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010; 303: 1832– 1840.
Oner P, Bekpinar S, Oz B. Alterations in some lipid components and Ca2+ ATPase activity in brains of rats fed an atherogenic diet. Res Commun Chem Pathol Pharmacol 1991; 72: 337–345.
Myers RH, Schaefer EJ, Wilson PW, D’Agostino R, Ordovas JM, Espino A, Au R, White RF, Knoefel JE, Cobb JL et al. Apolipoprotein E ε4 association with dementia in a population- based study: the Framingham study. Neurology 1996; 46: 673– 6677.
National Institute on Aging/Alzheimer’s Association Working Group. Apolipoprotein E genotyping in Alzheimer’s disease. Lancet 1996; 347: 1091–1095.
Yokes B. Apolipoprotein E genotyping in Turkish Alzheimer patients. Balk J Med Gen 2005; 8: 57–63.
Isbir T, Agaçhan B, Yilmaz H, Aydin M, Kara I, Eker D, Eker E. Interaction between apolipoprotein-E and angiotensin- converting enzyme genotype in Alzheimer’s disease. Am J Alzheimers Dis Other Demen 2001; 16: 205–210.
Lee SF, Shah S, Li H, Yu C, Han W, Yu G. Mammalian APH- 1 interacts with presenilin and nicastrin and is required for intramembrane proteolysis of amyloid-beta precursor protein and Notch. J Biol Chem 2002; 277: 45013–45019.
Luo WJ, Wang H, Li H, Kim BS, Shah S, Lee HJ, Thinakaran G, Kim TW, Yu G, Xu H. PEN-2 and APH-1 coordinately regulate proteolytic processing of presenilin 1. J Biol Chem 2003; 278: 7850–7854.
Wang R, Zhang YW, Zhang X, Liu R, Zhang X, Hong S, Xia K, Xia J, Zhang Z, Xu H. Transcriptional regulation of APH-1A and increased gamma-secretase cleavage of APP and Notch by HIF-1 and hypoxia. FASEB J 2006; 20: 1275–1277.
Poli M, Gatta LB, Lovati C, Mariani C, Galimberti D, Scarpini E, Biunno I, Musicco M, Dominici R, Albertini A et al. Interaction between the APOE ε4 allele and the APH-1b c + 651T > G SNP in Alzheimer’s Disease. Neurobiol Aging 2008; 29: 1494–1501.